Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

50.0%

4 terminated/withdrawn out of 8 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

50%

4 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

4(50.0%)

Phase 2

3(37.5%)

Phase 1

1(12.5%)

8Total

Phase 3(4)

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT04784455Phase 3Terminated

Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy

Role: lead

NCT03427060Phase 2Completed

Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms

Role: lead

NCT04035733Phase 2Completed

rVA576 in Adult Mild to Moderate Bullous Pemphigoid Subjects

Role: lead

NCT04037891Phase 1Terminated

Topical rVA576 for Treatment of Atopic Keratoconjunctivitis

Role: lead

NCT03829449Phase 3Terminated

rVA576 (Coversin) Long Term Safety and Efficacy Surveillance Study

Role: lead

NCT03588026Phase 3Completed

Treating Paroxysmal Nocturnal Haemoglobinuria Patients With rVA576

Role: lead

NCT05061771Phase 3Withdrawn

Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)

Role: lead

NCT02591862Phase 2Completed

Coversin in Paroxysmal Nocturnal Haemoglobinuria (PNH)

Role: lead

All 8 trials loaded